Names and pronunciation
(rye-ba-vye′rin) Ibavyr , Moderiba , Rebetol, Ribasphere, Ribasphere, RibaPak, Virazole
PDF page 1149
Loading InternPractice…
Drug reference
(rye-ba-vye′rin) Ibavyr , Moderiba , Rebetol, Ribasphere, Ribasphere, RibaPak, Virazole
PDF page 1149
Func. class.: Antiviral, nucleoside/ nucleotides
PDF page 1149
USES: Treatment of chronic HCV infection when used in combination; RSV infection in hospitalized children
PDF page 1149
CONTRAINDICATIONS Hypersensitivity, breastfeeding, preg- nancy, sickle cell disease, thalassemia, pancreatitis, CCr 50 mL/min
PDF page 1149
Black Box Warning: Monotherapy (RCV infection)
PDF page 1149
DOSAGE AND ROUTES Respiratory syncytial virus (RSV) infection • Infant/child/adolescent: INH ribavirin 20 mg/mL solution in the drug reservoir of the SPAG-2 unit, continuous aerosol administration for 12-18 hr/day × 3-7 days Chronic hepatitis C infection with compensated hepatic disease (Child-Pugh A) used in combination with a peginterferon alfa-2b • Adults >105 kg: PO (capsules/oral solution): 600 mg AM and 800 mg PM (1400 mg/day) plus peginterferon alfa- 2b; 81-105 kg: 600 mg bid (1200 mg/ day) plus peginterferon alfa-2b; 66-80 kg (1000 mg/day) 400 mg AM and 600 mg PM plus peginterferon alfa-2b; <66 kg 400 mg AM, 400 mg PM plus pe ginterferon-alpha-2b; duration genotype 1 48 wk; genotype 2 or 3 24 wk, any failure 48 wk • Adolescent >73 kg: PO (capsules) 15 mg/kg/day or 1200 mg/day given in 2 divided doses (3 capsules in the morning and evening) plus interferon alfa-2b. Du- ration for genotype 1 is 48 wk; genotype 2 or 3 is 24 wk • Child/adolescent 60-73 kg: PO (cap- sules) 15 mg/kg/day or 1000 mg/day given in 2 divided doses (2 capsules in the morning and 3 capsules in the eve- ning) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; genotype 2 or 3 is 24 wk • Child/adolescent 47-59 kg: PO (cap- sules) 15 mg/kg/day or 800 mg/day given in 2 divided doses (2 capsules in the morning and evening) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; genotype 2 or 3 is 24 wk • Child/adolescent 3-17 yr, <47 kg: PO (oral solution) 15 mg/kg/day given in 2 divided doses as the oral solution (in the morning and evening) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; genotype 2 or 3 is 24 wk Chronic hepatitis C infection in com- pensated hepatic disease (Child- Pugh A) with interferon alfa-2b alone • Adults >75 kg: PO (capsules/oral solution) 600 mg bid (in the morning and evening) plus interferon alfa-2b. For interferon-alfa-naive patients, treat for R 24-48 wk; ≤75 kg: PO (capsules/oral solution) 400 mg AM and 600 mg PM plus interferon alfa-2b. For interferon- alfa-naive patients, treat for 24-48 wk • Adolescent >73 kg: PO 15 mg/kg/day or 1200 mg/day in 2 divided doses (AM and PM) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; duration for genotype 2 or 3 is 24 wk • Child/adolescent 60-73 kg: PO 15 mg/ kg/day or 1000 mg/day given in 2 divided doses (AM and PM) plus interferon alfa- 2b. Duration for genotype 1 is 48 wk. Duration for genotype 2 or 3 is 24 wk • Child/adolescent 47-59 kg: PO 15 mg/kg/day or 800 mg/day given in 2 di- vided doses AM and PM) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; duration for genotype 2 or 3 is 24 wk • Child/adolescent 3-17 yr, <47 kg: PO 15 mg/kg/day given in 2 divided doses (AM and PM) plus interferon alfa-2b. Duration for genotype 1 is 48 wk; dura- tion for genotype 2 or 3 is 24 wk
PDF pages 1149, 1150
Available forms: Capsules 200 mg; tablets 200 mg, 800 mg/day, 1200 mg/day, 1000 mg/day; powder for nebulizer solution 6 g
PDF page 1150
• Infant/child/adolescent: INH ribavirin 20 mg/mL solution in the drug reservoir of the SPAG-2 unit, continuous aerosol administration for 12-18 hr/day × 3-7 days Chronic hepatitis C infection with compensated hepatic disease (Child-Pugh A) used in combination with a peginterferon alfa-2b
PDF pages 1149, 1150